About Immune Cell Therapy
ICT is developing a personalized vaccine treatment to help cancer from recurring. A small amount of the patient's own primary tumor is used to prepare the vaccine, so that the vaccine targets the specific cancer that the patient has. This personalized vaccine is much simpler and cheaper to produce than existing cancer vaccine therapies that are being tested. ICT has received approval from the FDA for its IND to begin clinical trials for lung cancer, which will initially be conducted at the University of Pittsburgh.
Latest Immune Cell Therapy News
Apr 18, 2023
Immune Cell Therapy Frequently Asked Questions (FAQ)
What is Immune Cell Therapy's latest funding round?
Immune Cell Therapy's latest funding round is Other Investors.
Who are the investors of Immune Cell Therapy?
Investors of Immune Cell Therapy include Capital Midwest Fund.